



您的位置: [首页](#)>> 文章摘要

## 硬皮病相关肺动脉高压的治疗

刘坚, 郭智, 于孟学

刘坚、于孟学, 中国医学科学院 中国协和医科大学 北京协和医院风湿免疫科, 100730; 郭智, 北京军区总医院

摘要: 肺动脉高压(pulmonary arterial hypertension, PAH)是系统性硬皮病(systemic scleroderma, SSc)的主要死因之一。相对于WHO疾病分类中其他类型的PAH, 现代医学对SSc相关PAH的治疗效果令人失望。本文总结了PAH的主要特点, 当前该病的治疗方法, 并对该病的治疗前景做一展望。

关键词: 硬皮病

[评论](#) [收藏](#) [全](#)

文献标引: 刘坚, 郭智, 于孟学. 硬皮病相关肺动脉高压的治疗[J/CD]. 中华临床医师杂志: 电子版, 2011, 5(4):

### 参考文献:

- [1] Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *Circulation*, 2004, 110(25): 5S-12S. [\[PubMed\]](#)
- [2] Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. *Coron Art Dis*, 2003, 13(1): 13-18. [\[PubMed\]](#)
- [3] Overbeek MJ, Lankhaar JW, Westerhof N, et al. Right ventricular contractility in systemic sclerosis associated and idiopathic pulmonary arterial hypertension. *Eur Respir J*, 2008, 31(6): 1253-1260. [\[PubMed\]](#)
- [4] Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in systemic sclerosis. *Chest*, 2003, 124(6): 2098-2104. [\[PubMed\]](#)
- [5] Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary arterial hypertension: the risk factors for severe pulmonary hypertension in scleroderma. *J Rheumatol*, 2006, 33(12): 2303-2308. [\[PubMed\]](#)
- [6] Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum*, 2007, 50(12): 2033-2040. [\[PubMed\]](#)
- [7] Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Left atrial volume and N-terminal pro-brain natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. *Clin Rheumatol*, 2010, 29(9): 957-964. [\[PubMed\]](#)
- [8] Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure in pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 2008, 177(12): 1364-1369. [\[PubMed\]](#)
- [9] Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in pulmonary arterial hypertension. *Circulation*, 2005, 111(23): 3105-3111. [\[PubMed\]](#)
- [10] Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue disease-associated pulmonary arterial hypertension. *Chest*, 2006, 130(1): 182-189. [\[PubMed\]](#)
- [11] Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of trepro-

### 期刊导读

6卷23期 2012年12月 [最新]



期刊存档

期刊存档

[查看目录](#)

### 期刊订阅



在线订阅



邮件订阅



RSS

### 作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

## 编委会

### 期刊服务



建议我们



会员服务



广告合作



继续教育

- prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind placebo-controlled trial. *Am J Respir Crit Care Med*, 2002, 165(6): 800-804. [\[PubMed\]](#)
- [12] Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. *Circulation*, 2005, 112(3): 683-688. [\[PubMed\]](#)
- [13] Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Am J Respir Crit Care Med*, 2000, 132(6): 425-434. [\[PubMed\]](#)
- [14] Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*, 2001, 358(9288): 1119-1123. [\[PubMed\]](#)
- [15] Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by prostanooids or sildenafil. *Rheumatology (Oxford)*, 2010, 49(3): 490-500. [\[PubMed\]](#)
- [16] Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. *J Heart Lung Transplant*, 2005, 24(10): 1626-1631. [\[PubMed\]](#)
- [17] Barst RJ, Langleben D, Frost A, et al. Sildenafil therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 2004, 169(4): 441-447. [\[PubMed\]](#)
- [18] Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with bosentan for pulmonary arterial hypertension associated with connective tissue disease. *Ann Rheum Dis*, 2005, 64(11): 1467-1472. [\[PubMed\]](#)
- [19] Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*, 2008, 117(10): 1287-1295. [\[PubMed\]](#)
- [20] Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol*, 2007, 34(12): 2417-2422. [\[PubMed\]](#)
- [21] Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. *Invest*, 2005, 115(6): 1461-1463. [\[PubMed\]](#)
- [22] Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension. *Thorax*, 2006, 61(8): 736. [\[PubMed\]](#)
- [23] McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral sildenafil in patients with pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol*, 2006, 48(15): 1915-1922. [\[PubMed\]](#)
- [24] Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Int Med*, 2006, 144(8): 521-530. [\[PubMed\]](#)
- [25] Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in patients with pulmonary arterial hypertension. *Eur Respir J*, 2007, 29(3): 469-475. [\[PubMed\]](#)
- [26] Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and importance of thrombosis. *Circulation*, 1984, 70(4): 580-587. [\[PubMed\]](#)

## 综 述

### 髓系抑制性细胞与脓毒症免疫抑制

杜中涛, 郁正亚. . 中华临床医师杂志: 电子版  
2011;5(4):1068-1071 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 颅底凹陷症的研究进展

汤四昌, 刘胜刚, 盛伟斌. . 中华临床医师杂志: 电子版

2011;5(4):1072-1074 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[机械应力刺激在脊柱韧带骨化发生中的作用](#)

许鹏, 何海龙, 叶晓健. . 中华临床医师杂志: 电子版  
2011;5(4):1075-1077 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[D2-40在肿瘤淋巴管标记及诊断的研究进展](#)

陈文静, 张江宇, 李文萍. . 中华临床医师杂志: 电子版  
2011;5(4):1078-1080.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[检测血液透析动静脉内瘘早期狭窄的新方法](#)

荣鹏, 孟建中, 景颖. . 中华临床医师杂志: 电子版  
2011;5(4):1081-1083 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[硬皮病相关肺动脉高压的治疗](#)

刘坚, 郭智, 于孟学. . 中华临床医师杂志: 电子版  
2011;5(4):1084-1087.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[胃网膜右动脉在冠状动脉旁路移植术中的应用进展](#)

张凤, 邓勇志. . 中华临床医师杂志: 电子版  
2011;5(4):1088-1091 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[核酸适配子在临床研究中的进展](#)

彭艳, 冯茂辉, 谢伟. . 中华临床医师杂志: 电子版  
2011;5(4):1092-1094 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[减肥手术改善2型糖尿病相关研究进展](#)

陈文娜, 严宗逊. . 中华临床医师杂志: 电子版  
2011;5(4):1095-1098.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[睾丸扭转的诊断治疗进展](#)

文焰林, 邓显忠, 廖波. . 中华临床医师杂志: 电子版  
2011;5(4):1099-1102 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[FcγR IIIB基因多态性与牙周炎易感性相关研究进展](#)

林琳, 丁一, 谢萍. . 中华临床医师杂志: 电子版  
2011;5(4):1103-1105 .

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)